IASO Biotherapeutics Funding Round

1/17/2023

Venture Equity

$75,000,000

Series C

The funding will support research and development of the company's pipeline products, and the commercial launch of its core product Equecabtagene Autoleucel.

Private & Independent

Biopharmaceutical

5th floor, No. 77-78,Lane 887, Zuchongzhi Road, Shanghai Pil
Shanghai, 201203
CN

IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully-human antibody discovery platform (IMARS), high-throughput CAR T drug screening platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This includes a diversified portfolio of over 10 novel pipeline products, including IASO's leading asset, Equecabtagene Autoleucel (CT103A), a fully human BCMA chimeric antigen receptor autologous T cell injection. Equecabtagene Autoleucel received New Drug Application (NDA) acceptance from China's National Medical Products Administration (NMPA) for the treatment of relapsed/refractory multiple myeloma (r/r MM).